RECRUITING

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

Official Title

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Quick Facts

Study Start:2019-05-21
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05181826

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 2.1.1 Age 18 years or older.
  2. 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .
  1. 2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded.
  2. 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.

Contacts and Locations

Study Contact

Clinical Operations Manager
CONTACT
6263500537
octavia@heliogenomics.com

Principal Investigator

Taggert
STUDY_DIRECTOR
Helio Health

Study Locations (Sites)

Torrance Memorial Physician Network - Cancer Care
Redondo Beach, California, 90277
United States
Allina Health, Virginia Piper Cancer Institute
Coon Rapids, Minnesota, 55433
United States
Virginia Piper Cancer Institute Mercy Hospital-Unity Campus
Fridley, Minnesota, 55432
United States
VPCI Oncology Research
Minneapolis, Minnesota, 55407
United States
Methodist LeBonheur Healthcare
Memphis, Tennessee, 38104
United States
Liver Center of Texas
Dallas, Texas, 75234
United States
Methodist Hospital
Richardson, Texas, 75082
United States

Collaborators and Investigators

Sponsor: Helio Genomics

  • Taggert, STUDY_DIRECTOR, Helio Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-05-21
Study Completion Date2025-12

Study Record Updates

Study Start Date2019-05-21
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Cancer
  • Liver Cirrhosis
  • Chronic Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Diabetes
  • COPD